Galmarini, Carlos Marķa <br/><br/>
Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.  [electronic resource] 

 -  International journal of cancer  Feb 2002 
 - 439-45 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0020-7136 
<br/><br/><label>Standard No.: </label>10.1002/ijc.1628  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--pathology<br/>Antimetabolites, Antineoplastic--pharmacology<br/>Apoptosis--drug effects<br/>Breast Neoplasms--pathology<br/>Cyclin-Dependent Kinase Inhibitor p21<br/>Cyclins--biosynthesis<br/>DNA Damage<br/>DNA Replication--drug effects<br/>DNA, Neoplasm--drug effects<br/>Deoxycytidine--analogs & derivatives<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>G1 Phase--drug effects<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Genes, Dominant<br/>Genes, bcl-2<br/>Genes, p53<br/>Humans<br/>Neoplasm Proteins--deficiency<br/>Neoplastic Stem Cells--drug effects<br/>Phenotype<br/>Proto-Oncogene Proteins c-bcl-2--biosynthesis<br/>RNA, Messenger--biosynthesis<br/>RNA, Neoplasm--biosynthesis<br/>S Phase--drug effects<br/>Tumor Cells, Cultured--drug effects<br/>Tumor Suppressor Protein p53--deficiency<br/>bcl-X Protein<br/>Gemcitabine